Immunotherapy plus chemotherapy before and after surgery for stage II head and neck cancer
Part of Cancer clinical trials.
This trial tests giving a drug called finotonlimab (an immunotherapy that helps your immune system fight cancer) together with chemotherapy before and after surgery for stage II head and neck cancer. The goal is to see if this combination can improve outcomes for patients, and you will receive the treatment as part of your standard surgical care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with stage II head and neck squamous cell carcinoma (a type of cancer that starts in the lining of the mouth, throat, or voice box), but not in the nasopharynx (the upper part of the throat behind the nose).
- Your tumor can be removed with surgery, and you are willing to have surgery.
- You have not had any previous treatment for this cancer, like radiation, chemotherapy, or immunotherapy.
- You are generally in good health (able to do light activity) and your major organs (like blood cells, liver, and kidneys) are working well enough.
- You are not pregnant or breastfeeding, and if you or your partner could have children, you agree to use effective birth control during the study and for 2 months after the last dose of the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests three drugs (finotonlimab, cetuximab, and docetaxel) given before surgery to remove recurrent head and neck cancer in patients whose cancer stopped responding to previous immunotherapy. The goal is to shrink the tumor and improve surgical outcomes.
This trial tests whether giving immunotherapy along with chemotherapy before surgery can help treat locally advanced head and neck cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
This trial tests a combination of an immunotherapy drug (tirelizumab) with two chemotherapy drugs before surgery for head and neck cancer that has spread to lymph nodes. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests a new immunotherapy drug (adelbelimab) combined with chemotherapy given before surgery, for people with head and neck cancer. The goal is to see if this combination can shrink the tumor and improve the chances of successful surgery.
This trial tests whether giving the immunotherapy drug tislelizumab with chemotherapy before surgery can help people with advanced head and neck cancer. The goal is to shrink the tumor enough to remove it completely during surgery.
This trial tests a combination of low-dose radiation and an immunotherapy drug (similar to Keytruda) given before surgery for advanced head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
Hear when a new Head and Neck Squamous Cell Carcinoma HNSCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.